Hillstream BioPharma Announces Share Repurchase Program
13 juin 2022 08h00 HE
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream BioPharma Provides Corporate Update
02 juin 2022 08h47 HE
|
Hillstream BioPharma, Inc.
Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent portfolio remain key competitive advantages...
Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
05 mai 2022 08h47 HE
|
Hillstream BioPharma, Inc.
Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences professionals and thought leadersHillstream’s...
Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II
19 mai 2020 08h00 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™)...
Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC)
06 janv. 2020 08h00 HE
|
Hillstream BioPharma, Inc.
Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUATRAMER formulation of a potent anti-Ferroptotic compounds,...
Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board
19 nov. 2019 07h00 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific...
Hillstream BioPharma Announces Collaboration with Ardena to Support QUATRAMER Manufacturing
04 nov. 2019 09h35 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for...
Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML
10 oct. 2019 09h35 HE
|
Hillstream BioPharma, Inc.
CHESTER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the renewal of a Cooperative Research and Development Agreement (CRADA) with the National...
Hillstream BioPharma Presents at 2017 Marcum MicroCap Conference in New York
12 juin 2017 12h40 HE
|
Hillstream Biosciences
CHESTER, N.J., June 12, 2017 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (Hillstream), a biopharmaceutical company focused on developing targeted, safer and more effective cancer therapeutics,...